Feasibility of Eliminating Ocular Chlamydia trachomatis With Repeat Mass Antibiotic Treatments | Cornea | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Taylor HR, Pacqué M, Muñoz B, Greene BM. Impact of mass treatment of onchocerciasis with ivermectin on the transmission of infection.  Science.1990;250:116-118.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2218502&dopt=AbstractGoogle Scholar
Henderson DA. Eradication: lessons from the past.  Bull World Health Organ.1998;76(suppl 2):17-21.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10063668&dopt=AbstractGoogle Scholar
Farid M. The malaria programme—from euphoria to anarchy.  World Health Forum.1980;1:8.Google Scholar
Dowdle WR. The principles of disease elimination and eradication.  Bull World Health Organ.1998;76(suppl 2):22-25.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10063669&dopt=AbstractGoogle Scholar
Wawer MJ, Sewankambo NK, Serwadda D.  et al. for the Rakai Project Study Group.  Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial.  Lancet.1999;353:525-535.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10028980&dopt=AbstractGoogle Scholar
World Health Organization.  Report of the First Meeting of the WHO Alliance for the Global Elimination of Trachoma. Geneva, Switzerland: World Health Organization; 1997.
Thylefors B, Négrel AD, Pararajasegaram R, Dadzie KY. Global data on blindness.  Bull World Health Organ.1995;73:115-121.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7704921&dopt=AbstractGoogle Scholar
Jones RB, Van der Pol B, Martin DH, Shepard MK. Partial characterization of Chlamydia trachomatis isolates resistant to multiple antibiotics.  J Infect Dis.1990;162:1309-1315.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2230260&dopt=AbstractGoogle Scholar
McOrist S. Obligate intracellular bacteria and antibiotic resistance.  Trends Microbiol.2000;8:483-486.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11121750&dopt=AbstractGoogle Scholar
Friederich R. Eye disease in the Navajo indians.  Ann Ophthalmol.1982;14:38-40.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7125439&dopt=AbstractGoogle Scholar
Lietman T, Porco T, Dawson C, Blower S. Global elimination of trachoma: how frequently should we administer mass chemotherapy?  Nat Med.1999;5:572-576.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10229236&dopt=AbstractGoogle Scholar
Kacena KA, Quinn SB, Howell MR, Madico GE, Quinn TC, Gaydos CA. Pooling urine samples for ligase chain reaction screening for genital Chlamydia trachomatis infection in asymptomatic women.  J Clin Microbiol.1998;36:481-485.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9466763&dopt=AbstractGoogle Scholar
Peeling RW, Toye B, Jessamine P, Gemmill I. Pooling of urine specimens for PCR testing: a cost saving strategy for Chlamydia trachomatis control programmes.  Sex Transm Infect.1998;74:66-70.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9634309&dopt=AbstractGoogle Scholar
Morré SA, Meijer CJ, Munk C.  et al.  Pooling of urine specimens for detection of asymptomatic Chlamydia trachomatis infections by PCR in a low-prevalence population: cost-saving strategy for epidemiological studies and screening programs.  J Clin Microbiol.2000;38:1679-1680.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10747169&dopt=AbstractGoogle Scholar
Diamont J, Moncada J, Pang F.  et al.  Pooling of chlamydial laboratory tests to determine prevalence of trachoma.  Ophthalmic Epidemiol.2001;8:109-117.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11471080&dopt=AbstractGoogle Scholar
Saltelli A, Chan K, Scott EM. Sensitivity AnalysisChichester, England: John Wiley & Sons; 2000.
Holm SO, Jha HC, Bhatta RC.  et al.  Comparison of two azithromycin distribution strategies for controlling trachoma in Nepal.  Bull World Health Organ.2001;79:194-200.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11285662&dopt=AbstractGoogle Scholar
Bird M, Dawson CR, Schachter JS.  et al.  Does the diagnosis of trachoma adequately identify ocular chlamydial infection in trachoma-endemic areas?  J Infect Dis.2003;187:1669-1673.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12721948&dopt=AbstractGoogle Scholar
Schachter J, West SK, Mabey D.  et al.  Azithromycin in control of trachoma.  Lancet.1999;354:630-635.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10466664&dopt=AbstractGoogle Scholar
Katz J, Zeger SL, West Jr KP, Tielsch JM, Sommer A. Clustering of xerophthalmia within households and villages.  Int J Epidemiol.1993;22:709-715.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8225747&dopt=AbstractGoogle Scholar
Murray DM. Design and Analysis of Group-Randomized TrialsNew York, NY: Oxford University Press; 1998.
Jha H, Chaudary J, Bhatta R.  et al.  Disappearance of trachoma in western Nepal.  Clin Infect Dis.2002;35:765-768.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12203176&dopt=AbstractGoogle Scholar
Dolin PJ, Faal H, Johnson GJ.  et al.  Reduction of trachoma in a sub-Saharan village in absence of a disease control programme.  Lancet.1997;349:1511-1512.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9167460&dopt=AbstractGoogle Scholar
Hoechsmann A, Metcalfe N, Kanjaloti S.  et al.  Reduction of trachoma in the absence of antibiotic treatment: evidence from a population-based survey in Malawi.  Ophthalmic Epidemiol.2001;8:145-153.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11471084&dopt=AbstractGoogle Scholar
Emerson PM, Cairncross S, Bailey RL, Mabey DC. Review of the evidence base for the "F" and "E" components of the SAFE strategy for trachoma control.  Trop Med Int Health.2000;5:515-527.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10995092&dopt=AbstractGoogle Scholar
Gaynor BD, Miao Y, Cevallos V.  et al.  Eliminating trachoma in areas with limited disease.  Emerg Infect Dis.2003;9:596-598.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12737745&dopt=AbstractGoogle Scholar
Fry AM, Jha HC, Lietman T.  et al.  Secondary effects of mass chemoprophylaxis with azithromycin to eliminate blindness due to trachoma in Nepal: adverse and beneficial effects.  Clin Infect Dis.2002;35:395-402.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12145722&dopt=AbstractGoogle Scholar
Brief Report
August 11, 2004

Feasibility of Eliminating Ocular Chlamydia trachomatis With Repeat Mass Antibiotic Treatments

Author Affiliations

Author Affiliations: ORBIS International, Addis Ababa, Ethiopia (Drs Melese and Alemayehu); WHO Collaborating Center, F.I. Proctor Foundation (Drs Chidambaram, Saidel, Whitcher, Gaynor, and Lietman, Mr Lee, and Mss Yi, Cevallos, Zhou, and Donnellan), Department of Ophthalmology (Drs Gaynor, Whitcher, and Lietman), Department of Epidemiology and Biostatistics (Drs Whitcher and Lietman), Institute for Global Health (Drs Whitcher and Lietman), University of California, San Francisco.

JAMA. 2004;292(6):721-725. doi:10.1001/jama.292.6.721

Context Mass antibiotic administrations for ocular chlamydial infection play a key role in the World Health Organization's trachoma control program. Mathematical models suggest that it is possible to eliminate trachoma locally with repeat mass treatment, depending on the coverage level of the population, frequency of mass treatments, and rate that infection returns into a community after each mass treatment. Precise estimates of this latter parameter have never been reported.

Objective To determine the rate at which chlamydial infection returns to a population after mass treatment and to estimate the treatment frequency required for elimination of ocular chlamydia from a community.

Design, Setting, and Participants Longitudinal cohort study of 24 randomly selected villages from the Gurage Zone in Ethiopia conducted February 2003 to October 2003. A total of 1332 children aged 1 to 5 years were monitored for prevalence of ocular chlamydial infection pretreatment and 2 and 6 months posttreatment.

Interventions All individuals older than 1 year were eligible for single-dose oral azithromycin treatment. Pregnant women were offered tetracycline eye ointment.

Main Outcome Measures Prevalence of ocular chlamydial infection, measured by polymerase chain reaction, in children aged 1 to 5 years, in each of 24 villages at each time point was used to estimate the rate of return of infection and the treatment frequency necessary for elimination.

Results The prevalence of infection was 56.3% pretreatment (95% confidence interval [CI], 47.5%-65.1%), 6.7% 2 months posttreatment (95% CI, 4.2%-9.2%), and 11.0% 6 months posttreatment (95% CI, 7.3%-14.7%). Infection returned after treatment at an exponential rate of 12.3% per month (95% CI, 4.6%-19.9% per month). The minimum treatment frequency necessary for elimination was calculated to be once every 11.6 months (95% CI, 7.2-30.9 months), given a coverage level of 80%. Thus, biannual treatment, already being performed in some areas, was estimated to be more than frequent enough to eventually eliminate infection.

Conclusion The rate at which ocular chlamydial infection returns to a community after mass treatment suggests that elimination of infection in a hyperendemic area is feasible with biannual mass antibiotic administrations and attainable coverage levels.